Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar.

Al Hail, Moza; Elkassem, Wessam; Hamad, Anas; Abdulrouf, Pallivalappila; Thomas, Binny; Stewart, Derek

Abstract

Adverse Drug Reactions (ADRs) are major global concern, adversely impacting patient safety and health outcomes. ADRs cause significant morbidity and mortality among hospitalised patients, causing greater length of hospital stay, increased healthcare costs and patient dissatisfaction to the treatments. Pharmacovigilance (PV), a process of detecting, monitoring and preventing drug-related harm, plays a vital role to ensure patient safety. ADR reporting is the cornerstone of PV. PV practices in Qatar are relatively new and are evolving rapidly. The purpose of this article is to explore the medication safety practices (notably ADR reporting) at the largest academic healthcare center in Qatar. The article further provides evidence on how information related to ADRs are generated and interpreted. Furthermore, it describes how a designated center for monitoring medication safety activities was established at the largest healthcare provider in Qatar.

Citation

AL HAIL, M., ELKASSEM, W., HAMAD, A., PALLIVALAPPILA, A., THOMAS, B. and STEWART, D. 2018. Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar. International journal of clinical pharmacy [online], 40(4), pages 769-774. Available from: https://doi.org/10.1007/s11096-018-0629-5

• Journal Article Type: Article
• Acceptance Date: Mar 6, 2018
• Online Publication Date: Apr 3, 2018
• Publication Date: Aug 30, 2018
• Deposit Date: May 15, 2018
• Publicly Available Date: Apr 4, 2019
• Journal: International journal of clinical pharmacy
• Print ISSN: 2210-7703
• Electronic ISSN: 2210-7711
• Publisher: Springer
• Peer Reviewed: Peer Reviewed
• Volume: 40
• Issue: 4
• Pages: 769-774
• DOI: https://doi.org/10.1007/s11096-018-0629-5
• Keywords: Adverse drug reactions; Hamad Medical Corporation; Medication safety; Pharmacovigilance; Qatar
• Public URL: http://hdl.handle.net/10059/2920